 Anandani Nellan
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebellar Neoplasms | 3 | 2024 | 150 | 1.450 |
Why?
| | Medulloblastoma | 3 | 2024 | 191 | 1.420 |
Why?
| | Brain Neoplasms | 6 | 2024 | 1143 | 1.200 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 209 | 0.750 |
Why?
| | Pituitary Diseases | 1 | 2020 | 21 | 0.710 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 36 | 0.690 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 26 | 0.680 |
Why?
| | Retinoblastoma | 1 | 2020 | 31 | 0.680 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.670 |
Why?
| | Glioma | 2 | 2020 | 347 | 0.630 |
Why?
| | Immunotherapy, Adoptive | 2 | 2019 | 295 | 0.590 |
Why?
| | Receptor, ErbB-2 | 1 | 2018 | 325 | 0.500 |
Why?
| | Antigens, CD19 | 1 | 2015 | 114 | 0.470 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 75 | 0.460 |
Why?
| | Ependymoma | 3 | 2022 | 161 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 757 | 0.410 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2019 | 704 | 0.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1554 | 0.370 |
Why?
| | Immunotherapy | 1 | 2015 | 590 | 0.360 |
Why?
| | Central Nervous System Neoplasms | 2 | 2022 | 146 | 0.310 |
Why?
| | Macaca mulatta | 2 | 2018 | 149 | 0.280 |
Why?
| | Administration, Intravenous | 2 | 2018 | 141 | 0.280 |
Why?
| | T-Lymphocytes | 4 | 2020 | 1932 | 0.270 |
Why?
| | Hedgehog Proteins | 2 | 2024 | 187 | 0.240 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1161 | 0.190 |
Why?
| | Vinblastine | 1 | 2020 | 70 | 0.170 |
Why?
| | Animals | 6 | 2024 | 35286 | 0.170 |
Why?
| | Carboplatin | 1 | 2020 | 139 | 0.170 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2020 | 282 | 0.160 |
Why?
| | Mutation | 3 | 2020 | 3705 | 0.160 |
Why?
| | B7 Antigens | 1 | 2019 | 12 | 0.160 |
Why?
| | Child, Preschool | 4 | 2020 | 10456 | 0.150 |
Why?
| | Infusions, Intraventricular | 1 | 2018 | 4 | 0.150 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 55 | 0.150 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 117 | 0.150 |
Why?
| | Administration, Intranasal | 1 | 2018 | 84 | 0.150 |
Why?
| | Mice | 4 | 2024 | 16905 | 0.150 |
Why?
| | Half-Life | 1 | 2018 | 162 | 0.150 |
Why?
| | Supratentorial Neoplasms | 1 | 2018 | 16 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 200 | 0.140 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1033 | 0.140 |
Why?
| | Area Under Curve | 1 | 2018 | 304 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 83 | 0.140 |
Why?
| | Blood-Brain Barrier | 1 | 2018 | 131 | 0.140 |
Why?
| | Autophagy | 1 | 2019 | 266 | 0.130 |
Why?
| | Cell Line, Tumor | 3 | 2019 | 3186 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4882 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2019 | 308 | 0.130 |
Why?
| | Dyskeratosis Congenita | 1 | 2015 | 4 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4056 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 195 | 0.120 |
Why?
| | Survival Rate | 1 | 2020 | 1869 | 0.120 |
Why?
| | Exoribonucleases | 1 | 2015 | 43 | 0.120 |
Why?
| | Child | 5 | 2022 | 20768 | 0.120 |
Why?
| | Male | 7 | 2020 | 63456 | 0.120 |
Why?
| | Microcephaly | 1 | 2015 | 87 | 0.120 |
Why?
| | Intellectual Disability | 1 | 2015 | 154 | 0.110 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2117 | 0.100 |
Why?
| | Cytokines | 1 | 2020 | 2012 | 0.100 |
Why?
| | Infant | 3 | 2020 | 8975 | 0.090 |
Why?
| | Humans | 11 | 2022 | 129144 | 0.090 |
Why?
| | Female | 5 | 2020 | 68494 | 0.080 |
Why?
| | Fetal Growth Retardation | 1 | 2015 | 550 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2022 | 14450 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2020 | 5736 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 627 | 0.070 |
Why?
| | Adolescent | 2 | 2020 | 20297 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 91 | 0.050 |
Why?
| | Leukocytes | 1 | 2022 | 306 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3766 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 97 | 0.040 |
Why?
| | Benzamides | 1 | 2019 | 203 | 0.040 |
Why?
| | Blotting, Western | 1 | 2019 | 1202 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1198 | 0.030 |
Why?
| | Cell Survival | 1 | 2019 | 1074 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 808 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 458 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2022 | 1336 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 874 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1155 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 390 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 382 | 0.030 |
Why?
| | Exome | 1 | 2015 | 220 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1678 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1683 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 12385 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7117 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2716 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5408 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 10192 | 0.010 |
Why?
| | Adult | 1 | 2018 | 35469 | 0.010 |
Why?
|
|
Nellan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|